Navigation Links
Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27
Date:10/13/2009

CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference. The company has initiated a Series B round of financing; it is seeking to raise $15 million to take the company through Phase II clinical trials with its lead drug candidate.

Cequent is using the company's proprietary TransKingdom RNA interference (tkRNAi) technology to develop RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease. The company has made considerable progress with its programs targeting polyposis and inflammatory bowel disease (IBD), demonstrating through in vivo testing and studies with non-human primates that its tkRNAi technology can silence target genes successfully. It expects to file its first IND (investigational new drug) application with the U.S. Food and Drug Administration for an orally administered tkRNAi drug targeting the primary oncogene in FAP (familial adenomatous polyposis) before the end of the quarter. FAP is a rare inherited gastrointestinal disease that causes hundreds to thousands of precancerous polyps to form in the colon, leading to colon cancer.

Cequent completed a $15 million Series A financing in June of 2007. Investors included Ampersand Ventures, Pappas Ventures, Yasuda, and the Novartis Option Fund.

2009 BIOCOM Investor Conference

The fourth annual BIOCOM Investor Conference takes place October 26 - 27, 2009, at the Hyatt Regency La Jolla, California. For more informat
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
4. Cequent Names Ted Hibben Chief Business Officer
5. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional ... China , as well as solid contributions from Korea, India ... / Middle East / Africa ... Germany , Turkey and the United ... grew 11%, excluding U.S. HPV sales, on demand across all customer classes. The ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... ... 29, 2015 , ... G-CON Manufacturing, Inc., the leading prefabricated ... generation cell therapy POD® design. The 2nd generation portfolio not only delivers design ... POD® design. , “G-CON first offered our miniPOD CT product line to ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... DuPont Leader at UN Food and ... Agriculture Conference, ROME, June 3 ... harvest from their land and help address the,strong and growing global demand ... Pioneer Hi-Bred, told a United Nations Food and,Agriculture Organization Conference being held ...
... JOLLA, Calif., June 3 DermTech, a biotechnology,company ... and other diseases, today announced that Herbert A. ... Fritsche is,Professor and Chief of Clinical Chemistry at ... experts in the development and validation of cancer,diagnostics ...
... GeneXpert(R) Test Menu in Canada and Mexico, ... announced that Health Canada issued a medical device ... Group B Streptococcus (GBS),and Xpert(TM) EV (enterovirus), for ... Xpert MRSA, which received Health Canada,license in January ...
Cached Biology Technology:More Can Be Done Now to Address the Growing Global Demand for Grain 2More Can Be Done Now to Address the Growing Global Demand for Grain 3DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... attacks in New York City prompted large increases in ... man-made and natural disasters. But, this funding has ... disaster funding distribution is deeply inefficient: huge cash infusions ... abruptly after interest wanes. These issues have exposed significant ...
... damage to the Fukushima 1 Nuclear Power Plant in 2011, ... of radioactive contamination on wild and cultivated plants. In a ... these experts examine the potential adverse effects of radioactivity on ... article focusing on the efforts of a research group led ...
... treat certain types of cancer protect the insulin-producing cells ... mellitus type 1 in mice. The medicine works by ... have been made by researchers from the University of ... of Southern Denmark working with researchers in Belgium, Italy, ...
Cached Biology News:Funding problems threaten US disaster preparedness 2Microalgae and aquatic plants can help to decrease radiopollution in the Fukushima area 2Cancer drug protects against diabetes 2
... wide range of next-generation features into a ... standard for flexible laboratory solutions. It puts ... pipetting, dilution, dispensing, and integrations into ... and flexible as it is efficient and ...
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
... the process and you reduce the chance ... the CEQ 8000. Developed using Beckman Coulters ... in capillary electrophoresis technology, the CEQ 8000 ... This system automatically fills the capillary array ...
... standard electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 13 ...
Biology Products: